Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Retreatment in EGFR-mutated NSCLC
NCT01933347Phase 2Completed
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Apr 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Disease Control Rate at 8 weeks. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01933347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933347.